Subcutaneous nivolumab: Advancing operational efficiency and patient-centred care in the NHS

Abstract

Get full access to this article

View all access options for this article.

References

Medicines and Healthcare products Regulatory Agency. MHRA authorises cancer treatment variation with an administration time of 3–5 min 2025. Available from: https://www.gov.uk/government/news/mhra-authorises-cancer-treatment-variation-with-an-administration-time-of-3-5-min (accessed 12th May 2025).

Bristol Myers Squibb Pharmaceuticals limited. Summary of Product Characteristics OPDIVO 600 mg/5 ml solution for injection. Available from: https://www.medicines.org.uk/emc/product/100807/smpc (accessed 16^th May 2025).

Jackisch

Muller

Dall

, et al. Subcutaneous trastuzumab for HER2 positive breast cancer—evidence and practical experience in 7 German centers. Geburtshilfe Frauenheilkd 2015; 75: 566–573.

Pivot

Gligorov

Muller

, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol 2013; 14: 962–970.

Pivot

Gligorov

Muller

, et al. Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol 2014; 25: 1979–1987.

Solal-Celigny

. Rituximab by subcutaneous route. Expert Rev Hematol 2015; 8: 147–153.

NHS England. NHS world first rollout of cancer jab that cuts treatment time by up to 75%. Available from: https://www.england.nhs.uk/2023/08/nhs-world-first-rollout-of-cancer-jab-that-cuts-treatment-time-by-up-to-75/ (accessed 12^th May 2025).

George

Bourlon

Chacon

, et al. Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T. JCO 2024; 42: LBA360LBA360.

Lonardi

Lugowska

Jackson

, et al. Checkmate 8KX: phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20). JCO 2021; 39: 2575–2575.

10.

Hadfield

Benjamin

Krell

, et al. The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations. Trends Cancer 2024; 10: 579–583.

11.

Dodhia

Parkes

Ghose

, et al. The NHS SACT capacity crisis: challenges and solutions. J Oncol Pharm Pract 2023; 0: 10781552231185050.

12.

Royal College of Radiologists. Letter to the Secretary of State for Health and Social Care – Capacity challenges in oncology departments preventing the effective delivery of cancer drugs. Available from: https://www.rcr.ac.uk/sites/default/files/letter1. Pdf (accessed 16^th May 2025).

13.

NHS England. NHS rolls out 5-min ‘super-jab’ for 15 cancers. Available from: https://www.england.nhs.uk/2025/04/nhs-rolls-out-5-min-super-jab-for-15-cancers/ (accessed 12th May 2025).

14.

Dodhia

Alves

, et al. Preference of subcutaneous trastuzumab & pertuzumab (Phesgo®) versus conventional intravenous infusions in breast cancer patients. J Oncol Pharm Pract 2022; 28: 33–34.

15.

Cook

Ashcroft

Fernandez

, et al. Benefits of switching from intravenous to subcutaneous daratumumab: perspectives from UK healthcare providers. Front Oncol 2023; 13: 1063144.

16.

Cappuzzo

Zvirbule

Korbenfeld

, et al. Primary results from IMscin002: a study to evaluate patient preferences and perceptions of health care professionals for atezolizumab subcutaneous versus intravenous for the treatment of NSCLC. JTO Clinical and Research Reports 2025; 6: 100815. ISSN 2666-3643.

17.

Bittner

Richter

Schmidt

. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs 2018; 32: 425–440.

18.

Moeller

Green

Ramnath

. Pros and cons of subcutaneous (SC) versus intravenous (IV) administration of immune checkpoint inhibitors in non-small cell lung cancer. Transl Lung Cancer Res 2024; 13: 1444–1449.

19.

Fathallah

Bankert

Balu-Iyer

. Immunogenicity of subcutaneously administered therapeutic proteins-a mechanistic perspective. AAPS J 2013; 15: 897–900.

20.

British Oncology Pharmacy Association (BOPA). BOPA Immunotherapy Specialist Advisory Group: Toolkit for Immunotherapy IV to SC switch. Available from: https://www.bopa.org.uk/toolkit-for-immunotherapy-iv-to-sc-switch/ (accessed 13^th May 2025).